The International Menopause Society - SFOG

More documents

Recommendations

Info

Secreted VEGF in T47-D cells in response to various Progestins 0 VEGF pg/mg protein (X10 -3 ) 1 2 3 4 5 6 7 Control Prog Prog + RU MPA MPA + RU N-EL N-EL + RU N-ONE N-ONE + RU * * * * All steroids used at 10 -8 M MPA= Medroxyprogesterone acetate; N-EL= norgestrel; N-ONE = norethindrone Hyder et al, 2001
Risk of BC from Estrogen+progesterone ( started within 3 years of menopause) < 2 years HR: 0.87 CI: 0.57 - 1.32 2 – 5 years HR: 1.01 CI: 0.72 - 1.41 5 – 10 years HR: 1.47 CI: 1.11 - 1.95 >10 years HR: 1.92 CI: 1.34 - 2.74 p for trend 0.002 E3N cohort Fournier et al J Clin Oncol 2009;27 :5138-43
Page 1 and 2: HRT idag och i morgon: mot lägre d
Page 3 and 4: jan-00 jul-00 jan-01 jul-01 jan-02
Page 5 and 6: Djup förtroendekris Risker och sä
Page 7 and 8: Postmenopausal Hormone Therapy: an
Page 9 and 10: ERT vs HRT Progestin related side e
Page 11 and 12: No uterus no problem !
Page 14 and 15: Progesterone and progestins can rea
Page 18 and 19: Breast stimulation a class effect
Page 20 and 21: HRT utan bröstpåverkan Är det m
Page 22 and 23: change in density from different pr
Page 24 and 25: Vaginal Maturation Index Placebo 10
Page 26 and 27: Mean number NUMBER OF MODERATE TO S
Page 28 and 29: Mean breast density (%) Mammographi
Page 30: Testosterone addition inhibits estr
Page 33 and 34: Tibolone and BC risk in healthy wom
Page 35 and 36: MLS 10 µg LNG/day Mirena 20 µg LN
Page 37 and 38: Raloxifene
Page 39: BZA 20 mg/ CEE 0.45 mg a 2 year RCT
Page 42 and 43: Mammary Gland Branching in Ducts fr
Page 44 and 45: Options for breast safety Regim VMS

The International Menopause Society - SFOG

Create successful ePaper yourself

Delete template?

Save as template?